New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
07:16 EDTVRTXVertex downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright downgraded Vertex Pharmaceuticals to Neutral with an $85 price target following yesterday's rally. The firm believes share are appropriately valued at current levels.
News For VRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
06:34 EDTVRTXObama to propose $215M for major medical program, CNBC says
Subscribe for More Information
January 29, 2015
10:00 EDTVRTXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTVRTXVertex downgraded at Maxim
Subscribe for More Information
09:07 EDTVRTXHead researchers of Vertex, Regeneron, Merck invited to White House, CNBC says
Subscribe for More Information
08:08 EDTVRTXVertex downgraded to Hold from Buy at Maxim
Subscribe for More Information
06:58 EDTVRTXVertex downgraded to Hold from Buy at Needham
Subscribe for More Information
January 28, 2015
18:21 EDTVRTXOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTVRTXVertex sees FY15 KALYDECO net revenues $560M-$580M
FY15 revenue consensus $1.19B. KALYDECO net revenues reflect use of KALYDECO by eligible patients in Australia following the completion of reimbursement discussions in late 2014; use of KALYDECO in some people in the United States with the R117H mutation following FDA approval in late 2014; the completion of reimbursement discussions for gating mutations in certain European countries; and use of KALYDECO in children with CF ages 2 to 5 with the G551D or other gating mutations in the United States, based on potential approval in March 2015. Vertex expects that its combined non-GAAP R&D and SG&A expenses in 2015 will be in the range of $1.05B-$1.1B. The increase as compared to 2014 is primarily a result of launch preparation activities for lumacaftor in combination with ivacaftor and the planned pivotal Phase 3 development program for VX-661 in combination with ivacaftor.
16:05 EDTVRTXVertex reports Q4 adjusted EPS (55c), consensus (65c)
Reports Q4 revenue $145M, consensus $137.49M. Reports Q4 revenues of $124M from KALYDECO in CF.
15:37 EDTVRTXNotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use